U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H23N5O3S
Molecular Weight 425.5059
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FILGOTINIB

SMILES

c1cc(-c2ccc(cc2)CN3CCS(=O)(=O)CC3)n4c(c1)nc(=NC(=O)C5CC5)[nH]4

InChI

InChIKey=RIJLVEAXPNLDTC-UHFFFAOYSA-N
InChI=1S/C21H23N5O3S/c27-20(17-8-9-17)23-21-22-19-3-1-2-18(26(19)24-21)16-6-4-15(5-7-16)14-25-10-12-30(28,29)13-11-25/h1-7,17H,8-14H2,(H,23,24,27)

HIDE SMILES / InChI

Molecular Formula C21H23N5O3S
Molecular Weight 425.5059
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including: http://adisinsight.springer.com/drugs/800032685 | http://www.glpg.com/docs/view/564327aec62e3-en | http://www.glpg.com/docs/view/5719315eea963-en

Filgotinib (GLPG0634) is a highly selective JAK1 inhibitor. GLPG0634 is a promising drug candidate for the future treatment of autoimmune and inflammatory disorders. It is in phase III clinical trials (initiated mid-2016) for the treatment of rheumatoid arthritis, Crohn's disease and ulcerative colitis. Most common adverse events observed were infections, gastrointestinal disorders and nervous system disorders.

Approval Year

Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2580 ng/mL
450 mg 1 times / day multiple, oral
dose: 450 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
FILGOTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
4.42 μg/mL
450 mg 1 times / day multiple, oral
dose: 450 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
FILGOTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1160 ng/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FILGOTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
10200 ng × h/mL
450 mg 1 times / day multiple, oral
dose: 450 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
FILGOTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
16.3 μg × h/mL
450 mg 1 times / day multiple, oral
dose: 450 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
FILGOTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
4844 ng × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FILGOTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.09 h
450 mg 1 times / day multiple, oral
dose: 450 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
FILGOTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
5.68 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FILGOTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
450 mg 1 times / day multiple, oral
Highest studied dose
Dose: 450 mg, 1 times / day
Route: oral
Route: multiple
Dose: 450 mg, 1 times / day
Sources: Page: p.6
healthy, ADULT
n = 47
Health Status: healthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 47
Sources: Page: p.6
Disc. AE: Skin rash...
AEs leading to
discontinuation/dose reduction:
Skin rash (grade 1, 2.1%)
Sources: Page: p.6
AEs

AEs

AESignificanceDosePopulation
Skin rash grade 1, 2.1%
Disc. AE
450 mg 1 times / day multiple, oral
Highest studied dose
Dose: 450 mg, 1 times / day
Route: oral
Route: multiple
Dose: 450 mg, 1 times / day
Sources: Page: p.6
healthy, ADULT
n = 47
Health Status: healthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 47
Sources: Page: p.6
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 110 uM]
no [IC50 140 uM]
no [IC50 151.6 uM]
no [IC50 158 uM]
no [IC50 168 uM]
no [IC50 188 uM]
no [IC50 90 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >105.8 uM]
no [IC50 >170 uM]
no [IC50 >200 uM]
no [IC50 >200 uM]
no [IC50 >224 uM]
no [IC50 >224 uM]
no [IC50 >224 uM]
no [IC50 >224 uM]
no [IC50 >224 uM]
no [IC50 >224 uM]
no [IC50 >224 uM]
no [IC50 >224 uM]
no [IC50 >224 uM]
no [IC50 >300 uM]
no [IC50 >300 uM]
no [IC50 >300 uM]
no [IC50 >300 uM]
no [IC50 >300 uM]
no [IC50 >300 uM]
no [IC50 >40 uM]
no [IC50 >50 uM]
no [IC50 >500 uM]
no [IC50 >60 uM]
no [IC50 >60 uM]
no [IC50 >60 uM]
no [IC50 >60 uM]
no [IC50 >60 uM]
no [IC50 >70.6 uM]
no [IC50 >70.6 uM]
no [IC50 >70.6 uM]
no [IC50 >70.6 uM]
no [IC50 >80 uM]
no [IC50 >80 uM]
no [IC50 >80 uM]
no [IC50 >80 uM]
no [IC50 >80 uM]
no
no
no
no
no
no
weak [IC50 >70.6 uM]
weak [IC50 >70.6 uM]
weak [IC50 >70.6 uM]
weak [IC50 >70.6 uM]
yes [IC50 10.9 uM]
yes [IC50 14.9 uM]
yes [IC50 5.21 uM]
yes [IC50 8.63 uM]
yes [IC50 8.7 uM]
Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

Daily dose range up to 200 mg
Route of Administration: Oral
Filgotinib inhibited IL-2– and IL-4–induced JAK1/JAK3/γc signaling and IFN-αB2–induced JAK1/TYK2 type II receptor signaling most potently. IC50 values ranged from 150 to 760 nM.
Substance Class Chemical
Created
by admin
on Sat Jun 26 04:10:59 UTC 2021
Edited
by admin
on Sat Jun 26 04:10:59 UTC 2021
Record UNII
3XVL385Q0M
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FILGOTINIB
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
GS-6034 FREE BASE
Code English
CYCLOPROPANECARBOXAMIDE, N-(5-(4-((1,1-DIOXIDO-4-THIOMORPHOLINYL)METHYL)PHENYL)(1,2,4)TRIAZOLO(1,5-A)PYRIDIN-2-YL)-
Systematic Name English
FILGOTINIB [USAN]
Common Name English
FILGOTINIB [WHO-DD]
Common Name English
FILGOTINIB [INN]
Common Name English
G-146034
Code English
G146034
Code English
N-(5-(4-((1,1-OXO-.LAMBDA.6-THIOMORPHOLIN-4-YL)METHYL)PHENYL((1,2,4)TRIAZOLO(1,5-A)PYRIDIN-2-YL)CYCLOPROPANECARBOXAMIDE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C129825
Created by admin on Sat Jun 26 04:11:00 UTC 2021 , Edited by admin on Sat Jun 26 04:11:00 UTC 2021
NCI_THESAURUS C1967
Created by admin on Sat Jun 26 04:11:00 UTC 2021 , Edited by admin on Sat Jun 26 04:11:00 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C155799
Created by admin on Sat Jun 26 04:11:00 UTC 2021 , Edited by admin on Sat Jun 26 04:11:00 UTC 2021
PRIMARY
ChEMBL
CHEMBL3301607
Created by admin on Sat Jun 26 04:11:00 UTC 2021 , Edited by admin on Sat Jun 26 04:11:00 UTC 2021
PRIMARY
FDA UNII
3XVL385Q0M
Created by admin on Sat Jun 26 04:11:00 UTC 2021 , Edited by admin on Sat Jun 26 04:11:00 UTC 2021
PRIMARY
EVMPD
SUB182273
Created by admin on Sat Jun 26 04:11:00 UTC 2021 , Edited by admin on Sat Jun 26 04:11:00 UTC 2021
PRIMARY
EPA CompTox
1206161-97-8
Created by admin on Sat Jun 26 04:11:00 UTC 2021 , Edited by admin on Sat Jun 26 04:11:00 UTC 2021
PRIMARY
PUBCHEM
49831257
Created by admin on Sat Jun 26 04:11:00 UTC 2021 , Edited by admin on Sat Jun 26 04:11:00 UTC 2021
PRIMARY
WIKIPEDIA
Filgotinib
Created by admin on Sat Jun 26 04:11:00 UTC 2021 , Edited by admin on Sat Jun 26 04:11:00 UTC 2021
PRIMARY
CAS
1206161-97-8
Created by admin on Sat Jun 26 04:11:00 UTC 2021 , Edited by admin on Sat Jun 26 04:11:00 UTC 2021
PRIMARY
INN
9720
Created by admin on Sat Jun 26 04:11:00 UTC 2021 , Edited by admin on Sat Jun 26 04:11:00 UTC 2021
PRIMARY
DRUG BANK
DB14845
Created by admin on Sat Jun 26 04:11:00 UTC 2021 , Edited by admin on Sat Jun 26 04:11:00 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY